Know Cancer

forgot password

GOAT; Phase I Single-Center Open Label Dose Escalation Study of CGTG-102, a GM-CSF Encoding Oncolytic Adenovirus, for Therapy of Advanced Cancers

Phase 1
18 Years
Not Enrolling
Tumors, Solid Tumors

Thank you

Trial Information

GOAT; Phase I Single-Center Open Label Dose Escalation Study of CGTG-102, a GM-CSF Encoding Oncolytic Adenovirus, for Therapy of Advanced Cancers

Pre-treatment visit - subject will undergo a physical examination with vital signs, a blood
sample will be taken and a PET (Positron emission tomography)-CT (Computer tomography) scan
will be performed.

Thereafter, there will be 4 visits with injections performed on trial days 1, 4, 8 and 15.


The injections are given directly into the tumors with help from using an ultrasound. The
total dose of oncolytic virus the subject will receive will be divided into 1-10 injections
which will be injected into individual tumors in the body. The maximum number of tumors that
can be injected for one treatment will be 10 tumors.


On the day 1 visit, blood samples will be taken as well as two biopsies from one of the
tumors. In addition pleural fluids (fluids from the chest) or ascites (fluids from abdominal
walls) may be collected if possible. Then the subject will receive the first set of
injections with CGTG-102. Before the injections, the subject may be given a dose of Tylenol.


On the day 4 visit, in addition to blood samples being taken the subject will receive a
second round of intratumoral injections into the same tumors selected for injections on day
1. Urine will also be collected right before the subject goes home.


The day 8 visit is identical to the day 4 visit. The same blood samples and urine sample are


On the day 15 visit blood samples and a urine sample will be taken as well as a biopsy from
one of the tumors.

Subjects will have to stay overnight at the hospital after each treatment.


A follow-up visit will be scheduled on days 29 where only blood samples and a urine sample
will be taken.

The end of trial visit is scheduled around day 43 where in addition to lab samples a PET-CT
scan will be performed.

Following day 43 the subject will be contacted by study staff at 6 week intervals for 3
months, then at 3 month intervals for up to one year and yearly thereafter.

Inclusion Criteria


1. Age 18 - 70 years

2. Histologically-confirmed, advanced/metastatic solid tumor that is relapsed and/or
refractory to standard therapy (progressive disease despite therapy).

3. Cancer is not surgically resectable for cure.

4. At least one measurable tumor mass by PETCT (i.e. PET-positive lesion that can
reliable be assessed for SUV (standard update value) peak/SUV max, typically
featuring longest diameter greater than or equal to 1 cm) and that can be injected by
direct visualization/palpitation or by imaging-guidance (ultrasound)

5. Tumor suitable for biopsy. Biopsy is to be performed twice during the study (day 1
and day 15). The aim is to biopsy the same tumor at these visits.

6. Expected survival for approximately 12 weeks or longer

7. Performance Status WHO (World Health Organization) 0-2

8. Total bilirubin less than or equal to ULN (Upper Limit of Normal)

9. AST (Aspartate transaminase), ALT (Alanine aminotransferase) less than or equal to
3.0 × ULN

10. Serum creatinine less than or equal to 1.5 x ULN

11. INR (International Normalized Ratio) less than or equal to 1.5 x ULN

12. Hematologic parameters: Patients can be transfused to meet these entry criteria:

1. Hemoglobin greater than or equal to 10 g/dL

2. Leucocytes greater than or equal to 2300/mL

3. platelet count greater than or equal to 75,000 plts/mm

13. Willing to participate as demonstrated by signed informed consent form.


1. Known brain metastases or glioma. Central Nervous System malignancy, including
carcinomatosis meningitis.

2. Tumor in the immediate pericardial vicinity

3. Use of high dose systemic corticosteroids or other immune suppressive medication
within 3 weeks of first treatment.

Note: patients taking low-dose corticosteroids for the treatment of nausea and/or
taking maintenance corticosteroids for adrenal insufficiency are permitted to enroll.

4. Known infection with HIV (Human immunodeficiency virus) as this would affect the
immune response of treatment or known underlying genetic immunodeficiency disease

5. Treatment of the injected tumor(s) with radiotherapy, chemotherapy, surgery, or an
investigational drug within 4 weeks prior to first treatment.

6. Use of anti-viral medication. [Patients who discontinue such medications within 7
days prior to first treatment may be eligible for this study.]

7. Recent thromboembolic event

8. Clinically significant active infection or uncontrolled medical condition considered
high risk for investigational new drug treatment (e.g. pulmonary, neurological,
cardiovascular, metabolic such as type 2 diabetes, clinically significant and/or
rapidly accumulating ascites, peri-cardial and/or pleural effusions)

9. Severe or unstable cardiac disease.

10. Current, active, progressing CNS (Central nervous system) malignancy, including
carcinomatosis meningitis (definitively surgically resected or irradiated metastases

11. Pulse oximetry O2 (oxygen) criterion <90% at rest on room air

12. Vaccination with a live virus (i.e. measles, mumps, rubella, etc) < 30 days prior to
first treatment

13. History of hepatic dysfunction, cirrhosis, hepatitis or malaria

14. Evidence of coagulation disorder

15. Women who are pregnant or nursing an infant

16. Previous organ transplant

Type of Study:


Study Design:

Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Safety of CGTC-102 in patients with solid tumors

Outcome Description:

To assess the safety of the maximum tolerated dose and/or maximum feasible dose of CGTG-102 administered by intratumoral injection in a patient population with unresectable, refractory solid tumors

Outcome Time Frame:

28 days

Safety Issue:


Principal Investigator

Martha M Pritchett, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Baylor College of Medicine


United States: Food and Drug Administration

Study ID:




Start Date:

December 2013

Completion Date:

December 2021

Related Keywords:

  • Tumors
  • Solid Tumors
  • Tumors
  • Solid Tumors



The Methodist HospitalHouston, Texas  77030
Harris County Hospital District Ben TaubHouston, Texas  77030